Companion animal therapeutics, parasiticides and equine gastrointestinal products dominate latest approvals
The U.S. Food and Drug Administration Center for Veterinary Medicine (CVM) approved several new animal health products and generic veterinary drugs during April 2026, reflecting continued growth in:
- companion animal therapeutics
- parasiticides
- pain management
- equine gastrointestinal medicine
- veterinary generics
The latest approvals highlight broader industry trends shaping the global animal health market, including:
- expansion of pet healthcare
- increasing demand for chronic disease management
- growth of veterinary specialty medicine
- rising generic competition
- long-acting parasite-control technologies
According to the FDA’s recent animal drug approval records, the following major approvals were issued during April 2026.
Major FDA Animal Health Approvals — April 2026
| Approval Date | Company | Product | Species | Indication |
|---|---|---|---|---|
| April 29, 2026 | Ceva Santé Animale | AMODIP® | Cats | Systemic hypertension |
| April 29, 2026 | First Priority Inc. | Moxidectin Oral Drench | Sheep | Internal parasites |
| April 20, 2026 | Norbrook Laboratories | Loxicom® | Dogs | Osteoarthritis pain & inflammation |
| April 8, 2026 | Cronus Pharma Specialities India | Florfinasone™ Otic | Dogs | Otitis externa |
| April 6, 2026 | Bimeda Animal Health | Gastrobim™ | Horses | Gastric ulcers |
Source: FDA CVM Green Book
